The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | The challenges of treating BPDCN and the role of diagnostic markers
Naveen Pemmaraju, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, discusses the challenges of treating blastic plasmacytoid dendritic cell neoplasm (BPDCN) and gives an overview of current treatment strategies. Dr Pemmaraju talks on the approval of tagraxofusp for the treatment of BPDCN and IMGN632, and the potential future role of a novel CD123 antibody-drug conjugate which is currently under investigation. Dr Pemmaraju also comments on the increased acknowledgement of central nervous system involvement in BPDCN which may shape the future of research in the field. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
